Clinical Scorecard: Sex Does Not Modify Asthma Attack Predictors
At a Glance
| Category | Detail |
|---|---|
| Condition | Asthma |
| Key Mechanisms | Type 2 biomarkers (blood eosinophil count, fractional exhaled nitric oxide) predict asthma attack risk similarly in both sexes. |
| Target Population | Patients aged 12 years or older with asthma. |
| Care Setting | Clinical trials and patient-level meta-analysis. |
Key Highlights
- Female patients had a higher annualized severe asthma attack rate than male patients.
- Prior asthma attack history is the strongest predictor of future attacks, with sex-based differences in prognostic strength.
- Higher levels of type 2 biomarkers correlate with increased attack rates in both sexes.
- Patients with severe obesity have the highest attack rates, regardless of sex.
- Sex-stratified randomization in clinical trials may address baseline risk imbalances.
Guideline-Based Recommendations
Diagnosis
- Utilize blood eosinophil count and fractional exhaled nitric oxide for risk stratification.
Management
- Consider individual risk factors, including obesity and prior attack history, in treatment plans.
Monitoring & Follow-up
- Regularly assess asthma control and symptom scores, particularly in female patients.
Risks
- Female patients without recent attacks may still be at elevated risk for future attacks.
Patient & Prescribing Data
Patients with asthma, particularly those with severe obesity.
Inclusion of patients with severe obesity in clinical trials is essential for accurate risk assessment.
Clinical Best Practices
- Implement biomarker-guided risk stratification in clinical practice.
- Monitor female patients closely, especially those with a history of severe attacks.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.